

# CITATION REPORT

List of articles citing

## Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

DOI: 10.1016/j.jacc.2016.03.520

Journal of the American College of Cardiology, 2016, 67, 2578-89.

**Source:** <https://exaly.com/paper-pdf/63889961/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
606	Challenges and novel approaches for investigating molecular mediation. <b>2016</b> , 25, R149-R156		66
605	Progress in the care of familial hypercholesterolaemia: 2016. <b>2016</b> , 205, 232-6		12
604	Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond. <b>2016</b> , 23, 891-900		29
603	Statins in Familial Hypercholesterolemia: Translating Evidence to Action. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 261-264	15.1	5
602	Enough Evidence, Time to Act!. <b>2016</b> , 134, 20-3		1
601	Genetic identification of familial hypercholesterolemia within a single U.S. health care system. <b>2016</b> , 354,		229
600	Genetics: Implications for Prevention and Management of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2797-2818	15.1	65
599	Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2761-2772	15.1	127
598	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <b>2016</b> , 22, 1-32		60
597	Challenges in the health economics of familial hypercholesterolemia. <b>2016</b> , 27, 563-569		8
596	Familial Hypercholesterolemia: Now Part of Cardiovascular Disease Genetic Epidemiology Research. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2590-2	15.1	2
595	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. <b>2016</b> , 12, 467-84		22
594	Dyslipidaemia: FH genes, beyond LDL-C, predict CAD. <b>2016</b> , 13, 314		
593	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. <b>2016</b> , 32, 1552-1560		10
592	Diagnosis and Management of Individuals With Heterozygous Familial Hypercholesterolemia: Too Late and Too Little. <b>2016</b> , 134, 710-2		11
591	Under-Recognised and Underestimated: The Cardiovascular Health Burden of Familial Hypercholesterolaemia. <b>2016</b> , 25, 1045-1047		1
590	Familial Hypercholesterolemia: Advances in Recognition and Therapy. <b>2016</b> , 59, 125-134		8

589	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. <b>2016</b> , 134, 698-709	79
588	Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). <b>2016</b> , 36, 2004-10	102
587	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <b>2016</b> , 10, 1223-9	41
586	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. <b>2016</b> , 36, 2439-2445	130
585	Report of the American College of Cardiology (ACC) Scientific Sessions 2016, Chicago. <b>2016</b> , 80, 1308-13	2
584	Novel Therapies for Familial Hypercholesterolemia. <b>2016</b> , 18, 64	4
583	What Should Be the Screening Strategy for Familial Hypercholesterolemia?. <b>2016</b> , 375, 1685-1686	11
582	The panorama of familial hypercholesterolemia in Latin America: a systematic review. <b>2016</b> , 57, 2115-2129	20
581	Modern Management of Familial Hypercholesterolemia. <b>2016</b> , 14, 463-467	5
580	My Approach to the Patient With Familial Hypercholesterolemia. <b>2016</b> , 91, 770-86	22
579	Genetics of CHD in 2016: Common and rare genetic variants and risk of CHD. <b>2017</b> , 14, 73-74	7
578	Premature coronary artery disease in India: coronary artery disease in the young (CADY) registry. <b>2017</b> , 69, 211-216	30
577	Child-Parent Familial Hypercholesterolemia Screening in Primary Care. <b>2017</b> , 376, 499-500	10
576	Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. <b>2017</b> , 11, 260-271	53
575	Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. <b>2017</b> , 135, 2091-2101	244
574	Reply: Familial Hypercholesterolemia: Independent Malignity and LDLR Variant Databases. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 755	15.1
573	Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). <b>2017</b> , 135, 2133-2144	182
572	Genetics of coronary artery disease: discovery, biology and clinical translation. <b>2017</b> , 18, 331-344	267

571	Editor-in-Chief's Top Picks From 2016: Part Two. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1010-1042	15.1	
570	Screening for Hypercholesterolemia in Children: What Strategies Can Be Employed. <b>2017</b> , 11, 1		2
569	LDLR Variant Databases and Familial Hypercholesterolemia Population Studies. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 754-755	15.1	3
568	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. <b>2017</b> , 33, 658-665		12
567	Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. <b>2017</b> , 28, 144-151		12
566	Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening. <b>2017</b> , 28, 136-143		7
565	The role of registries and genetic databases in familial hypercholesterolemia. <b>2017</b> , 28, 152-160		35
564	Genetics of Dyslipidemia and Ischemic Heart Disease. <b>2017</b> , 19, 46		13
563	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <b>2017</b> , 38, 2459-2472		1267
562	Genetic Architecture of Familial Hypercholesterolaemia. <b>2017</b> , 19, 44		57
561	A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. <b>2017</b> , 41, 10-17		12
560	Can we afford not to screen for FH?. <b>2017</b> , 38, 1840-1842		6
559	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. <b>2017</b> , 121, 81-88		48
558	Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys. <b>2017</b> , 166, 876-882		11
557	Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening. <b>2017</b> , 166, 901-902		4
556	New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. <b>2017</b> , 24, 1200-1205		10
555	Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. <b>2017</b> , 28, 321-327		11
554	Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?. <b>2017</b> , 28, 130-135		10

553	Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world?. <b>2017</b> , 38, 1580-1583	42
552	A novel approach to screening for familial hypercholesterolemia in a large public venue. <b>2017</b> , 8, 35-44	10
551	Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?. <b>2017</b> , 263, 316-317	1
550	Improving Universal Pediatric Lipid Screening. <b>2017</b> , 188, 87-90	20
549	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. <b>2017</b> , 103, 1670-1679	18
548	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <b>2017</b> , 11, 880-890	73
547	Recent advances in genetic testing for familial hypercholesterolemia. <b>2017</b> , 17, 641-651	42
546	Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. <b>2017</b> , 263, 405-411	47
545	[Congenital disorders of lipoprotein metabolism]. <b>2017</b> , 42, 449-458	2
544	The Independent Malignity of Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 753-754	15.1
543	Molecular basis of familial hypercholesterolemia. <b>2017</b> , 32, 262-266	18
542	Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. <b>2017</b> , 260, 67-74	50
541	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. <b>2017</b> , 33, 343-349	13
540	Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. <b>2017</b> , 37, 570-579	36
539	Issues and Challenges in Diagnostic Sequencing for Inherited Cardiac Conditions. <b>2017</b> , 63, 116-128	6
538	Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals. <b>2017</b> , 166, 219-220	7
537	The continuing challenge of familial hypercholesterolaemia. <b>2017</b> , 3, 253-255	1
536	Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1732-1740	15.1 79

535	Is ACS in Young Patients a "Canary in the Coal Mine" for Familial Hypercholesterolemia?. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1741-1743	15.1	1
534	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. <b>2017</b> , 11, 1448-1457		32
533	Monogenetic disorders of the cholesterol metabolism and premature cardiovascular disease. <b>2017</b> , 816, 146-153		3
532	Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bolívar, Venezuela. <b>2017</b> , 64, 432-439		
531	Heterozygous Null Mutation in a Familial Hypercholesterolemia Patient With an Atypical Presentation Because of Alcohol Abuse. <b>2017</b> , 10,		3
530	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. <b>2017</b> , 11, 1338-1346.e7		30
529	LDL cholesterol level in fifth-grade schoolchildren associates with stature. <b>2017</b> , 58, 2197-2201		5
528	Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. <b>2017</b> , 7, e016461		160
527	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1785-1822	15.1	247
526	Polygenic determinants in extremes of high-density lipoprotein cholesterol. <b>2017</b> , 58, 2162-2170		33
525	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. <b>2017</b> , 136, 1878-1891		92
524	The evolving model of care for familial hypercholesterolaemia. <b>2017</b> , 24, 1729-1732		3
523	Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults. <b>2017</b> , 92, 1167-1168		
522	Knowns and unknowns in the care of pediatric familial hypercholesterolemia. <b>2017</b> , 58, 1765-1776		29
521	Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bolívar, Venezuela. <b>2017</b> , 64, 432-439		1
520	Statins for children with familial hypercholesterolemia. <b>2017</b> , 7, CD006401		27
519	Rapidly progressive atherosclerosis after domino liver transplantation from a teenage donor with homozygous familial hypercholesterolemia. <b>2017</b> , 11, 1284-1288		6
518	Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia. <b>2017</b> , 5, 933-943		

517	Familial hypercholesterolaemia. <b>2017</b> , 3, 17093	190
516	Clinical Application of Genetic Testing in Heart Failure. <b>2017</b> , 14, 543-553	4
515	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. <b>2017</b> , 7, 15282	24
514	An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study". <b>2017</b> , 7, e017817	23
513	Putting Into Perspective the Hazards of Untreated Familial Hypercholesterolemia. <b>2017</b> , 6,	3
512	The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia. <b>2017</b> , 11, 80-86	45
511	Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. <b>2017</b> , 256, 134-145	9
510	Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study. <b>2017</b> , 33, 385-392	17
509	Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia. <b>2017</b> , 24, 133-136	6
508	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. <b>2017</b> , 38, 1573-1579	78
507	Nurse-led cascade screening for FH: filling in the gaps. <b>2017</b> , 12, 60-61	
506	Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics. <b>2017</b> , 32, 36-40	9
505	Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. <b>2017</b> ,	0
504	The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. <b>2017</b> , 12, e0181148	24
503	Cardiovascular Disease and its Risk Factors in Patients with Familial Hypercholesterolemia: A Systematic Review. <b>2017</b> , 08,	
502	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. <b>2018</b> , 41, 378-384	23
501	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. <b>2018</b> , 34, 1004-1009	16
500	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. <b>2018</b> , 9, 1613	55

499	Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. <b>2018</b> , 104, 1600-1607	30
498	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. <b>2018</b> , 71, 1010-1017	4
497	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. <b>2018</b> , 12, 958-965	32
496	Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. <b>2018</b> , 54, 741-747	11
495	Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk. <b>2018</b> , 41, 385-391	12
494	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. <b>2018</b> , 103, 1704-1714	30
493	Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women. <b>2018</b> , 137, 820-831	18
492	PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. <b>2018</b> ,	78
491	Familial hypercholesterolemia: experience from France. <b>2018</b> , 29, 65-71	16
490	Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study. <b>2018</b> , 269, 106-116	19
489	Prevalence of high cholesterol levels suggestive of familial hypercholesterolemia in Brazilian adolescents: Data from the study of cardiovascular risk in adolescents. <b>2018</b> , 12, 403-408	6
488	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. <b>2018</b> , 71, 1010-1017	17
487	Predicting cardiovascular disease in familial hypercholesterolemia. <b>2018</b> , 29, 299-306	21
486	Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. <b>2017</b> , 82, 218-223	8
485	Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. <b>2018</b> , 274, 41-46	46
484	A New Approach to an Old Problem: One Brave Idea. <b>2018</b> , 122, 1172-1175	3
483	[Familial hypercholesterolemia: A largely underestimated cardiovascular risk]. <b>2018</b> , 67, 1-8	5
482	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <b>2018</b> , 64, 355-362	32



481	Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. <b>2018</b> , 137, 222-232	53
480	Primary Prevention of Atherosclerotic Cardiovascular Disease. <b>2018</b> , 433-458	
479	Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?. <b>2018</b> , 29, 445-452	13
478	Genetic testing for a patient with suspected familial hypercholesterolaemia. <b>2018</b> , 2018,	2
477	p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro. <b>2018</b> , 8, 16614	3
476	Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. <b>2018</b> , 11, e002352	9
475	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. <b>2018</b> , 57, 3551-3557	6
474	How well can familial hypercholesterolemia be identified in an electronic health record database?. <b>2018</b> , 10, 1667-1677	4
473	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <b>2018</b> , 34, 1553-1563	58
472	Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol. <b>2018</b> , 8, e023636	9
471	Genetic investigation into an increased susceptibility to biliary atresia in an extended New Zealand MBri family. <b>2018</b> , 11, 121	3
470	A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia. <b>2018</b> , 11, e002385	12
469	Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters. <b>2018</b> , 10,	6
468	Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program. <b>2018</b> , 11,	7
467	Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil. <b>2018</b> , 277, 464-469	1
466	A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STRategy). <b>2018</b> , 277, 369-376	4
465	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. <b>2018</b> , 277, 448-456	12
464	Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania. <b>2018</b> , 277, 267-272	4

463	Familial Hypercholesterolemia. <b>2018</b> , 285-297	
462	Epidemiology of familial hypercholesterolaemia: Community and clinical. <b>2018</b> , 277, 289-297	19
461	Familial hypercholesterolemia treatments: Guidelines and new therapies. <b>2018</b> , 277, 483-492	72
460	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <b>2018</b> , 277, 419-424	10
459	The development of the Mexican Familial Hypercholesterolemia (FH) National Registry. <b>2018</b> , 277, 517-523	2
458	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. <b>2018</b> , 12, 1436-1444	46
457	Use of plasma metabolomics to analyze phenotype-genotype relationships in young hypercholesterolemic females. <b>2018</b> , 59, 2174-2180	1
456	Unusual genetic variants associated with hypercholesterolemia in Argentina. <b>2018</b> , 277, 256-261	12
455	Preliminary data of familial hypercholesterolemia (FH) patients in Romania. <b>2018</b> , 277, 304-307	3
454	Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. <b>2018</b> , 12, 203-212	2
453	What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? <b>2018</b> , 277, 341-346	10
452	Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. <b>2018</b> , 277, 457-463	28
451	Latvian registry of familial hypercholesterolemia: The first report of three-year results. <b>2018</b> , 277, 347-354	6
450	Genetics of Coronary Atherosclerosis. <b>2018</b> , 33-44	
449	Healthcare Utilization and Patients' Perspectives After Receiving a Positive Genetic Test for Familial Hypercholesterolemia. <b>2018</b> , 11, e002146	12
448	Familial Hypercholesterolaemia Diagnosis and Management. <b>2018</b> , 13, 14-20	18
447	ClinVar database of global familial hypercholesterolemia-associated DNA variants. <b>2018</b> , 39, 1631-1640	55
446	How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. <b>2018</b> , 20, 138	3

445	Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study. <b>2018</b> , 8,	5
444	Simplified Canadian Definition for Familial Hypercholesterolemia. <b>2018</b> , 34, 1210-1214	36
443	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. <b>2018</b> , 20, 31	13
442	PCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?. <b>2018</b> , 12, 1106-1108	3
441	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. <b>2018</b> , 12, 972-980.e1	11
440	Pediatric lipid reference values in the general population: The Dutch lifelines cohort study. <b>2018</b> , 12, 1208-1216	18
439	Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales. <b>2018</b> , 275, 80-87	7
438	Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels. <b>2018</b> , 12, 1327-1328	3
437	[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians]. <b>2018</b> , 47, e159-e167	2
436	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. <b>2018</b> , 9, 707	22
435	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 662-680	15.1 215
434	Genetic testing for familial hypercholesterolemia among survivors of acute coronary syndrome. <b>2018</b> , 284, 674-684	7
433	Genetic Markers for Coronary Artery Disease. <b>2018</b> , 54,	8
432	Associations of common variants at ALDH2 gene and the risk of stroke in patients with coronary artery diseases undergoing percutaneous coronary intervention. <b>2018</b> , 97, e0711	4
431	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol $\geq 190$ mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. <b>2018</b> , 11, e004652	25
430	Lipid Screening, Action, and Follow-up in Children and Adolescents. <b>2018</b> , 20, 80	9
429	Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. <b>2018</b> , 9, 3391	90
428	Low-Density Lipoprotein Cholesterol: Is 160 the New 190?. <b>2018</b> , 138, 2326-2329	8

427	The Cardiovascular Burden of Undiagnosed Familial Hypercholesterolemia: Need to Modify Guidelines to Encourage Earlier Diagnosis and Therapy. <b>2018</b> , 34, 1112-1113		3
426	HDL-cholesterol, genetics, and coronary artery disease: the myth of the 'good cholesterol'?. <b>2018</b> , 39, 2179-2182		8
425	Genome-first findings require precision phenotyping. <b>2018</b> , 20, 1510-1511		4
424	Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. <b>2018</b> , 25, 751-770		97
423	Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol $\geq 190$ mg/dl from the Veterans Affairs Health System. <b>2018</b> , 122, 756-761		17
422	A snapshot of lipid levels in the Republic of Ireland in 2017. <b>2019</b> , 188, 241-247		3
421	The complex molecular genetics of familial hypercholesterolaemia. <b>2019</b> , 16, 9-20		112
420	Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing. <b>2019</b> , 132, 1279-1284		
419	Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects. <b>2019</b> , 287, 140-146		5
418	Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 512-522	15.1	67
417	Polygenic Risk Scores in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 523-525	15.1	3
416	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. <b>2019</b> , 19, 61		20
415	Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias. <b>2019</b> , 8, e012415		11
414	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. <b>2019</b> , 62, 414-422		14
413	Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. <b>2019</b> , 16, 467-478		
412	Rare Genetic Variants Associated With Sudden Cardiac Death in Adults. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2623-2634	15.1	17
411	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <b>2019</b> , 1, e393-e402		24
410	Genetic variations in familial hypercholesterolemia and cascade screening in East Asians. <b>2019</b> , 7, e00520		8

409	Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. <b>2019</b> , 7, 880-886	14
408	Screening auf familiäre Hypercholesterinämie in einer pädiatrischen Praxis [Ein wichtiger Beitrag zur Prävention von CVD. <b>2019</b> , 169, 941	
407	Behandlung einer familiären Hypercholesterinämie in einer pädiatrischen Praxis [Case Report. <b>2019</b> , 54, 186-188	
406	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <b>2019</b> , 289, 85-93	35
405	Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. <b>2019</b> , 1, 225-230	4
404	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. <b>2019</b> , 1, 190-197	2
403	Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. <b>2019</b> , 139, e56-e528	3937
402	Lipid-Lowering Agents. <b>2019</b> , 124, 386-404	87
401	Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. <b>2019</b> , 139, 1593-1602	112
400	A Japanese case of familial hypercholesterolemia with a novel mutation in the gene. <b>2019</b> , 28, 19-22	1
399	Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia. <b>2019</b> , 6, 5	15
398	A microwave absorbing material with soft magnetic nanoparticles based on negative refraction loss characteristics. <b>2019</b> , 56, 305-314	6
397	Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. <b>2019</b> , 21, 68	23
396	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <b>2019</b> , 287, 89-92	20
395	A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH). <b>2019</b> , 23, 547-553	3
394	Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia. <b>2019</b> , 1, 115-118	6
393	Low Rates of Identification and Treatment of Familial Hypercholesterolemia in France and Elsewhere: A Call for Universal Screening. <b>2019</b> , 35, 699-700	
392	Functional analysis of new variants at the low-density lipoprotein receptor associated with familial hypercholesterolemia. <b>2019</b> , 40, 1181-1190	9

391	WITHDRAWN: Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <b>2019</b> , 39, 100006		1
390	The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia. <b>2019</b> , 23, 100354		2
389	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <b>2019</b> , 286, 40-45		6
388	Hypercholesterolemia Among Premature 'Infarcts: Time to Start the Clock of Familial Hypercholesterolemia' Assessment. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2451-2453 <sup>15.1</sup>		1
387	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2439-2450	15.1	45
386	Status of PCSK9 Monoclonal Antibodies in Australia. <b>2019</b> , 28, 1571-1579		6
385	Polygenic Hypercholesterolemia and Cardiovascular Disease Risk. <b>2019</b> , 21, 43		21
384	Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. <b>2019</b> , 177, 587-596.e9		265
383	Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. <b>2019</b> , 39, 1172-1181		19
382	Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. <b>2019</b> , 19, 106		6
381	How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?. <b>2019</b> , 284, 218-220		
380	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2019</b> , 140, e596-e646		898
379	Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. <b>2019</b> , 70, 726-736		7
378	[PCSK9 inhibitors: What place in the management of dyslipidemia?]. <b>2019</b> , 48, 227-237		3
377	Value of Measuring Lipoprotein(a) During 'Cascade Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1029-1039	15.1	60
376	LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. <b>2019</b> , 13, 279-286		25
375	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1376-1414	15.1	463
374	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, e177-e232	15.1	516

373	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2019</b> , 140, e563-e595	192
372	Finding missed cases of familial hypercholesterolemia in health systems using machine learning. <b>2019</b> , 2, 23	30
371	Prevalence and Treatment of Familial Hypercholesterolemia in France. <b>2019</b> , 35, 744-752	5
370	What special considerations must be made for the pharmacotherapeutic management of heterozygous familial hypercholesterolemia?. <b>2019</b> , 20, 1175-1180	1
369	Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States. <b>2019</b> , 9,	11
368	Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. <b>2019</b> , 26, 1262-1270	16
367	Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. <b>2019</b> , 139, e603-e634	108
366	Statins for children with familial hypercholesterolemia. <b>2019</b> , 2019,	19
365	Monogenic, polygenic, and oligogenic familial hypercholesterolemia. <b>2019</b> , 30, 300-306	11
364	Genetic risk scores in lipid disorders. <b>2019</b> , 34, 406-412	3
363	The biochemical and genetic diagnosis of lipid disorders. <b>2019</b> , 30, 56-62	13
362	Familial Hypercholesterolaemia Registry in the MENA Region. <b>2020</b> , 18, 65-67	
361	Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy. <b>2019</b> , 8,	7
360	Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. <b>2019</b> , 30, 82-87	5
359	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <b>2019</b> , 8, e013225	44
358	Genes Potentially Associated with Familial Hypercholesterolemia. <b>2019</b> , 9,	11
357	Special Commentary: Is diet management helpful in familial hypercholesterolemia?. <b>2019</b> , 22, 135-140	12
356	Editorial Comment: Hyperlipidaemia and cardiovascular disease and impact of early cholesterol accumulation. <b>2019</b> , 30, 490-493	2



355	Screening and management of familial hypercholesterolemia. <b>2019</b> , 34, 526-530		9
354	Behandlungsoptionen bei schweren Hypercholesterinämien. <b>2019</b> , 19, 31-34		1
353	Genetics of early-onset coronary artery disease: from discovery to clinical translation. <b>2019</b> , 34, 706-713		5
352	Improving the detection of familial hypercholesterolaemia. <b>2019</b> , 51, 213-221		7
351	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <b>2019</b> , 13, 15-30		28
350	The role of genetic testing in dyslipidaemia. <b>2019</b> , 51, 184-192		25
349	Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. <b>2019</b> , 281, 25-30		20
348	DNA Sequence Variation in Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. <b>2019</b> , 68, 226-234		12
347	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> . <b>2019</b> , 73, e285-e350	15.1	895
346	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2019</b> , 139, e1046-e1081		187
345	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <b>2019</b> , 139, e1082-e1143		836
344	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> . <b>2019</b> , 73, e1144-e1202	15.1	654
343	Reclassifying Risk in Familial Hypercholesterolemia: The Power of a Coronary Artery Calcium Score of Zero. <b>2019</b> , 12, 1805-1807		9
342	Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH. <b>2019</b> , 281, 145-147		1
341	Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction. <b>2019</b> , 42, 385-390		7
340	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. <b>2019</b> , 13, 123-128		11
339	Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes. <b>2019</b> , 42, 591-598		6
338	Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia. <b>2019</b> , 21, 1173-1180		20



337	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. <b>2020</b> , 30, 151-157	2
336	Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: A protocol. <b>2020</b> , 16, 390-395	5
335	Statin therapy for young adults: A long-term investment worth considering. <b>2020</b> , 30, 48-53	5
334	Clinical significance of zero coronary artery calcium in individuals with LDL cholesterol $\geq 190$ mg/dL: The Multi-Ethnic Study of Atherosclerosis. <b>2020</b> , 292, 224-229	16
333	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. <b>2020</b> , 97, 257-263	3
332	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. <b>2020</b> , 5, 217-229	85
331	The familial hypercholesterolaemia phenotype: Monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. <b>2020</b> , 97, 457-466	15
330	Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. <b>2020</b> , 63, 103831	26
329	Very high LDL cholesterol: The power of zero passes another test. <b>2020</b> , 292, 207-208	4
328	Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. <b>2020</b> , 29, 619-633	11
327	Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study. <b>2020</b> , 11, 453-465	0
326	Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?. <b>2020</b> , 97, 543-555	6
325	Genetic Testing in Inherited Heart Diseases. <b>2020</b> , 29, 505-511	14
324	Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. <b>2020</b> , 287, 2-18	44
323	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. <b>2020</b> , 5, 1452-1453	
322	Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. <b>2020</b> , 52, 1169-1177	51
321	Type 1 diabetes mellitus, familial hypercholesterolemia, and elevated lipoprotein (a). <b>2020</b> , 33, 398-400	
320	The evaluation and management of patients with LDL-C $\geq 190$ mg/dL in a large health care system. <b>2020</b> , 1, 100002	0

319	Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?. <b>2020</b> , 22, 44	8
318	Chest pain triage: do genetics have a role?. <b>2020</b> , 9, 729-730	
317	Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor. <b>2020</b> , 11, 554931	2
316	GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study. <b>2020</b> , 10, 19336	3
315	Evinacumab in Patients with Refractory Hypercholesterolemia. <b>2020</b> , 383, 2307-2319	69
314	Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 703-714	15.1 22
313	The Role of Statins in Current Guidelines. <b>2020</b> , 22, 50	8
312	Molecular screening of familial hypercholesterolemia in Icelanders. <b>2020</b> , 80, 508-514	2
311	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. <b>2020</b> , 7, 113	2
310	Familial hypercholesterolaemia: New directions on the diagnosis and treatment of an old disease. <b>2020</b> , 61, 404-406	1
309	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <b>2020</b> , 2047487320942996	5
308	Prevalence and Characteristics of Patients With Primary Severe Hypercholesterolemia in a Multidisciplinary Healthcare System. <b>2020</b> , 132, 59-65	5
307	Genetic Diagnosis of Familial Hypercholesterolemia in Asia. <b>2020</b> , 11, 833	8
306	Cardiometabolic risk factors in siblings from a statewide screening program. <b>2020</b> , 14, 762-771	0
305	Treatment of heterozygous familial hypercholesterolemia: what does the future hold?. <b>2020</b> , 13, 1229-1234	3
304	The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?. <b>2021</b> , 7, 435-441	2
303	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. <b>2020</b> , 16, 1279-1287	5
302	Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?. <b>2020</b> , 22, 146	4

301	"Cholesterol-Years" for ASCVD Risk Prediction and Treatment. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1517-1520	15.1	4
300	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. <b>2020</b> , 13, 515-523		13
299	Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges. <b>2020</b> , 106, 1940-1946		10
298	Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. <b>2020</b> , 40, 2747-2755		1
297	Genetics, Screening, and Treatment of Familial Hypercholesterolemia: Experience Gained From the Implementation of the Vietnam Familial Hypercholesterolemia Registry. <b>2020</b> , 11, 914		3
296	Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. <b>2020</b> , 11, 3635		88
295	Universal cholesterol screening of youth-Are pediatric lipidologists smarter than a fifth grader?. <b>2020</b> , 14, 747-750		
294	Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. <b>2020</b> , 31, 347-355		8
293	Prevalence, treatment, and control of severe hyperlipidemia. <b>2020</b> , 3, 100079		1
292	Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants.. <b>2022</b> , 9, 370-380		0
291	Cascade screening and genetic diagnosis of familial hypercholesterolemia in clusters of the Southeastern region from Brazil. <b>2020</b> , 47, 9279-9288		0
290	Familial Hypercholesterolemia in Premature Acute Coronary Syndrome. Insights from CholeSTEMI Registry. <b>2020</b> , 9,		3
289	Genetics of Familial Hypercholesterolemia: New Insights. <b>2020</b> , 11, 574474		15
288	Verification of Underlying Genetic Cause in a Cohort of Russian Patients with Familial Hypercholesterolemia Using Targeted Next Generation Sequencing. <b>2020</b> , 7,		10
287	Perspectives from individuals with familial hypercholesterolemia on direct contact in cascade screening. <b>2020</b> , 29, 1142-1150		3
286	What Is Familial Hypercholesterolemia, and Why Does It Matter?. <b>2020</b> , 141, 1760-1763		14
285	Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. <b>2020</b> , 3, e203959		31
284	When a "normal" cholesterol level is not normal: Exposing an unusual presentation of familial hypercholesterolemia. <b>2020</b> , 14, 414-418		

283	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2682-2693	15.1	24
282	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. <b>2020</b> , 141, 1742-1759		117
281	The brave new world of genetic testing in the management of the dyslipidaemias. <b>2020</b> , 35, 226-233		7
280	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. <b>2020</b> , 13, e002725		26
279	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. <b>2020</b> , 298, 52-57		5
278	Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care. <b>2020</b> , 16, 11-25		13
277	Design and Reporting Considerations for Genetic Screening Tests. <b>2020</b> , 22, 599-609		6
276	Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. <b>2020</b> , 13, 23		23
275	Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. <b>2020</b> , 5, 390-399		71
274	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <b>2020</b> , 17, 360-377		41
273	Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. <b>2020</b> , 4, bvz015		6
272	Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. <b>2020</b> , 141, e139-e596		2824
271	Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia. <b>2020</b> , 14, 331-338		2
270	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. <b>2020</b> , 14, 346-351.e9		8
269	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. <b>2020</b> , 16, e1008629		49
268	Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. <b>2020</b> , 126, 1159-1177		44
267	Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels. <b>2020</b> , 11, 278		20
266	Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. <b>2021</b> , 31, 205-215		20

265	Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. <b>2021</b> , 117, 1154-1165	10
264	High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients. <b>2021</b> , 117, 109-122	12
263	Personalized medicine for cardiovascular diseases. <b>2021</b> , 66, 67-74	8
262	Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia. <b>2021</b> , 74, 664-673	2
261	Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia. <b>2021</b> , 3, 41-47	0
260	Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. <b>2021</b> , 22, 483-495	4
259	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. <b>2021</b> , 15, 33-60	33
258	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. <b>2021</b> , 160, 1620-1633.e13	20
257	Familial hypercholesterolemia and cardiovascular disease in older individuals. <b>2021</b> , 318, 32-37	3
256	Management of Familial Hypercholesterolemia: Current Status and Future Perspectives. <b>2021</b> , 5, bvaa122	5
255	PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. <b>2019</b> , 2047487319886140	
254	Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. <b>2021</b> ,	2
253	Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. <b>2021</b> ,	4
252	Impact of Diet on Plasma Lipids in Individuals with Heterozygous Familial Hypercholesterolemia: A Systematic Review of Randomized Controlled Nutritional Studies. <b>2021</b> , 13,	2
251	A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency. <b>2021</b> ,	2
250	Past, Present, and Future of Familial Hypercholesterolemia Management. <b>2021</b> , 17, 28-35	0
249	Influence of Habitual Dairy Food Intake on LDL Cholesterol in a Population-Based Cohort. <b>2021</b> , 13,	1
248	Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. <b>2021</b> , 143, e254-e743	1087

247	Patients With and Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. <b>2021</b> , 10, e018263	4
246	Machine learning modelling of blood lipid biomarkers in familial hypercholesterolaemia versus polygenic/environmental dyslipidaemia. <b>2021</b> , 11, 3801	1
245	Familial Hypercholesterolemia: Update and Review. <b>2021</b> ,	0
244	Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia. <b>2021</b> , 14, e003120	6
243	Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data. <b>2021</b> , 10,	2
242	The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives. <b>2021</b> , 32, 112-116	3
241	Polygenic Risk Score for Low-Density Lipoprotein Cholesterol Is Associated With Risk of Ischemic Heart Disease and Enriches for Individuals With Familial Hypercholesterolemia. <b>2021</b> , 14, e003106	5
240	Genetische Diagnostik in der Kardiologie - wann ist es sinnvoll?. <b>2021</b> , 21, 34-39	
239	Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. <b>2021</b> , 24, e00202	3
238	Closing the gap: Identification and management of familial hypercholesterolemia in an integrated healthcare delivery system. <b>2021</b> , 15, 347-357	3
237	Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis. <b>2021</b> , 8, 617249	3
236	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <b>2021</b> , 320, 1-9	1
235	Genetic Risk Assessment for Atherosclerotic Cardiovascular Disease: A Guide for the General Cardiologist. <b>2021</b> ,	1
234	Associations and limited shared genetic aetiology between bipolar disorder and cardiometabolic traits in the UK Biobank. <b>2021</b> , 1-10	4
233	Ancestrally and Temporally Diverse Analysis of Penetrance of Clinical Variants in 72,434 Individuals.	0
232	A Comprehensive Analysis of Genomics and Metagenomics in a Heterozygote Familial Hypercholesterolemia Family. <b>2021</b> , 11, 605954	1
231	Personalized medicine in lipid-modifying therapy. <b>2021</b> , 18, 185-203	0
230	Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. <b>2021</b> , 15, 375-378	1

229	Multiparametric profiling of cellular lipid metabolism in hypercholesterolemia.	
228	Polygenic risk scores: how much do they add?. <b>2021</b> , 32, 157-162	3
227	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <b>2021</b> , 10, e019254	1
226	Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia. <b>2021</b> , 116, 706-712	0
225	Genetic basis of hypercholesterolemia in adults. <b>2021</b> , 6, 28	4
224	Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia. <b>2021</b> , 66, 1079-1087	2
223	A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. <b>2021</b> , 23, 1697-1704	2
222	The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. <b>2021</b> , 11,	6
221	ANKS1A genotype predicts cardiovascular events in patients with familial hypercholesterolemia. <b>2021</b> , 15, 602-607	0
220	Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey. <b>2021</b> , 20, 45	1
219	Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. <b>2021</b> , 11,	1
218	Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis. <b>2021</b> ,	
217	Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?. <b>2021</b> , 23, 47	1
216	Exome sequence association study of levels and longitudinal change of cardiovascular risk factor phenotypes in European Americans and African Americans from the Atherosclerosis Risk in Communities Study. <b>2021</b> , 45, 651-663	0
215	The year 2020 in Atherosclerosis. <b>2021</b> , 326, 35-44	0
214	Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. <b>2021</b> , 12,	0
213	Variable and Severe Phenotypic Expression of the "Lebanese Allele" in Two Sisters with Familial Hypercholesterolemia. <b>2021</b> , 17, 415-419	1
212	Familial Hypercholesterolemia: Do HDL Play a Role?. <b>2021</b> , 9,	0

- 211 Characterization of familial hypercholesterolemia in Taiwanese ischemic stroke patients. **2021**, 13, 19339-19350
- 210 Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia. **2021**, 21, 887-895 0
- 209 Knowing More Than the Knowns in Familial Hypercholesterolemia. **2021**, 6, 909
- 208 Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesterolemia. **2021**, 134, 992-1001.e41 1
- 207 [32/F-Has a 38-year-old brother with heart attack and wants to protect herself : Preparation for the medical specialist examination: part 76]. **2021**, 62, 501-505
- 206 A framework for integrated clinical risk assessment using population sequencing data. 0
- 205 Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study. **2021**, 16, e0255345 0
- 204 Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease. **2021**, 37, 1733-1742 1
- 203 Finding inhibitors for PCSK9 using computational methods. **2021**, 16, e0255523 3
- 202 Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis. **2021**, 6, 902-909 2
- 201 Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement. **2021**, 100, 529-541 2
- 200 Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. 2
- 199 Hypercholesterolemia at a young age. **2021**, 17, 83-93
- 198 Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia. **2021**, 23, 64 0
- 197 Cutaneous manifestations in familial hypercholesterolaemia. **2021**, 333, 116-123 0
- 196 Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography. **2021**, 12, 0
- 195 Polygenic risk score and coronary artery disease: A meta-analysis of 979,286 participant data. **2021**, 333, 48-55 2
- 194 Risk Prediction Using Polygenic Risk Scores for Prevention of Stroke and Other Cardiovascular Diseases. **2021**, 52, 2983-2991 2



193	Characterization of Two Variants at Met 1 of the Human Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes. <b>2021</b> , 9,	1
192	Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey. <b>2021</b> ,	1
191	Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. <b>2021</b> , 117, 782-844	1
190	Advances in familial hypercholesterolaemia in children. <b>2021</b> , 5, 652-661	5
189	Lower-Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia. <b>2021</b> , 10, e020800	2
188	Familial hypercholesterolaemia: too many lost opportunities. <b>2021</b> , 398, 1667-1668	
187	Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland. <b>2021</b> , 41, 2616-2628	4
186	Familial Hypercholesterolaemia in the Malaysian Community: Prevalence, Under-Detection and Under-Treatment. <b>2021</b> , 28, 1095-1107	3
185	Hypercholesterolemia risk associated Abca6 does not regulate lipoprotein metabolism in mice or hamster. <b>2021</b> , 1866, 159006	0
184	Differences in pediatric cholesterol screening rates between family physicians and pediatricians correlate with conflicting guidelines. <b>2021</b> , 153, 106732	1
183	Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. <b>2021</b> ,	2
182	Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia. <b>2021</b> ,	2
181	Familial hypercholesterolemia. <b>2021</b> , 323-348	0
180	Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions.. <b>2021</b> , 2, 100025	0
179	Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. <b>2021</b> , 23, 4	5
178	Familial hypercholesterolemia in Mexico: Initial insights from the national registry. <b>2021</b> , 15, 124-133	7
177	A systematic review of LDLR, PCSK9, and APOB variants in Asia. <b>2020</b> , 305, 50-57	3
176	Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. <b>2020</b> , 308, 32-38	3

175	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <b>2020</b> , 42, e30-e34		2
174	Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2567-2569	15.1	12
173	ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia. <b>2020</b> , 14, 207-217.e7		16
172	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <b>2020</b> , 14, 398-413		29
171	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <b>2021</b> , 28, 875-883		7
170	Hyperlipidemia and cardiovascular disease with focus on familial hypercholesterolemia. <b>2017</b> , 28, 445-447		7
169	Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?. <b>2020</b> , 31, 111-118		8
168	Polygenic background modifies penetrance of monogenic variants conferring risk for coronary artery disease, breast cancer, or colorectal cancer.		5
167	Phenotypic Associations and Shared Genetic Etiology between Bipolar Disorder and Cardiometabolic Traits.		1
166	Genome-wide polygenic score to identify a monogenic risk-equivalent for coronary disease.		13
165	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease.		4
164	Barriers, facilitators, and solutions to familial hypercholesterolemia treatment. <b>2020</b> , 15, e0244193		3
163	Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. <b>2017</b> , 66, S1-S9		12
162	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. <b>2021</b> ,		3
161	Whole genome sequence analysis of blood lipid levels in >66,000 individuals.		0
160	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. <b>2021</b> , 11, 20421		0
159	Familial hypercholesterolemia: case series of a rare condition. <b>2021</b> , 26, 4610		1
158	Genetic testing for Familial Hypercholesterolaemia - Past, Present and Future. <b>2021</b> , 100139		1

- 157 Heterozygous Familial Hyperlipidemia in a Fighter Pilot. **2021**, 92, 835-837
- 156 Pro a p dem prohran ouboj proti PCSK9 inhibitor m. **2021**, 67, 3-8
- 155 Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. **2021**, 2
- 154 Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. **2021**, 10, 2
- 153 A physically fit woman in her thirties with exertional dyspnoea. **2017**, 137, 456-458
- 152 . **2017**, 106, 921-926 O
- 151 Atherosclerosis: Pathogenesis, Genetics and Experimental Models. 1-10
- 150 Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. 4
- 149 New Treatments on the Horizon for Familial Hypercholesterolemia. **2017**, 32, 447-448
- 148 OBSOLETE: Familial Hypercholesterolemia. **2018**,
- 147 Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk. **2018**, 111, 104-108 1
- 146 Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia. **2018**, 111, 578-584 O
- 145 Predictors of Family Recruitment in a Program of Genetic Cascade Screening for Familial Hypercholesterolemia. **2018**, 111, 585-586
- 144 A Review of Pediatric Cardiovascular Risk Factors and Current Guidelines. **2018**, 08, 61-92
- 143 Coronary artery disease risk and lipidomic profiles are similar in familial and population-ascertained hyperlipidemias. 1
- 142 Molecular Screening of Familial Hypercholesterolemia in the Icelandic Population.
- 141 [Diagnosis and Treatment of Familial Hypercholesterolemia]. **2018**, 107, 1345-1353
- 140 Consensus statement of professional associations on prescribing of PCSK9-inhibitors. **2018**, 64, 1131-1136 5

139 Familial Hypercholesterolemia. **2019**, 185-198

138 How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. **2019**, 15, 16-22

1

137 Polygenic Hyperlipidemias and Coronary Artery Disease Risk.

136 Resilience to dominant genetic disease in the healthy elderly.

135 Population-specific and transethnic genome-wide analyses reveal distinct and shared genetic risks of coronary artery disease.

134 Rare Loss-of-function Mutations of PTGIR Identified in Fibromuscular Dysplasia and Spontaneous Coronary Artery Dissection.

133 Familial Hypercholesterolemie in Deutschland. **2020**, 9, 363-369

132 Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. **2021**,

0

131 Encyclopedia of Behavioral Medicine. **2020**, 1-4

130 Encyclopedia of Behavioral Medicine. **2020**, 896-899

129 The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. **2021**, 179-200

128 Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach-Reply. **2020**, 5, 1453

127 Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. **2021**, 107-120

126 The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests. **2021**, 335-364

125 Cardiovascular Genomics. **2021**, 81-89

124 Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Historical Cholesterol Exposure.

123 Hipercolesterolemia familiar: serie de 36 casos con fenotipo de hipercolesterolemia familiar homocigica. **2020**, 27, 498-507

122 Rendimiento diagnóstico de la secuenciación de genes de hipercolesterolemia familiar en sujetos con hipercolesterolemia primaria. **2020**, 74, 664-664

1

121	DNA sequencing in familial hypercholesterolaemia: the next generation. <b>2021</b> , 28, 873-874	0
120	Chinese Guideline on the Primary Prevention of Cardiovascular Disease. <b>2021</b> , Publish Ahead of Print,	2
119	Patient voice and health education for familial hypercholesterolaemia. 001789692110559	
118	Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.. <b>2021</b> ,	1
117	Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report. <b>2021</b> ,	0
116	Clinical utility of polygenic risk scores for coronary artery disease. <b>2021</b> ,	7
115	Role of an automated screening tool for familial hypercholesterolemia in patients with premature coronary artery disease. <b>2022</b> , 48, 1-1	
114	A Case of Heterozygous Familial Hypercholesterolemia: Success of Long-Term Management. <b>2022</b> , 403-412	
113	Letter by Tromp et al Regarding Article, "Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland".. <b>2022</b> , 42, e44-e45	
112	Severe Combined Hyperlipidemia and Multiple Medication Sensitivities. <b>2022</b> , 421-436	
111	An Overview on the Role of Statins in Dyslipidemia Management in Primary Health Care. <b>2021</b> , 10, 33-37	
110	Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.. <b>2022</b> , CIR0000000000001052	196
109	How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?. <b>2022</b> ,	1
108	Population-Based Penetrance of Deleterious Clinical Variants.. <b>2022</b> , 327, 350-359	3
107	Individualized Treatment for Patients With Familial Hypercholesterolemia.. <b>2022</b> , 11, 39-54	1
106	Low Detection Rates of Genetic FH in Cohort of Patients With Severe Hypercholesterolemia in the United Arab Emirates.. <b>2021</b> , 12, 809256	0
105	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure.. <b>2022</b> , CIRCGEN121003501	2
104	Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease: Molecular Basis to Clinical Diagnosis and Epidemiologic Burden.. <b>2022</b> , 106, 325-348	1

103	Multiparametric platform for profiling lipid trafficking in human leukocytes.. <b>2022</b> , 2, 100166		0
102	Calcified and Noncalcified Coronary Plaques and Atherosclerotic Cardiovascular Events in Patients With Severe Hypercholesterolemia-Moving Forward With Risk Stratification and Therapy.. <b>2022</b> , 5, e2148147		
101	Novel Protein-Truncating Variant in the <i>APOB</i> Gene Protects from Coronary Artery Disease: Results from a Pilot-Analysis of Targeted Next-Generation Sequencing of Genes Regulating Cholesterol Homeostasis within a Cardiovascular Cohort.		
100	Effect of the Consumption of Alcohol-Free Beers with Different Carbohydrate Composition on Postprandial Metabolic Response.. <b>2022</b> , 14,		
99	A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021.. <b>2022</b> , 101151		1
98	Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 617-628	15.1	5
97	Key Questions About Familial Hypercholesterolemia: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1023-1031	15.1	2
96	Phenotypic and genotypic characterization of familial hypercholesterolemia in French adult and pediatric populations.. <b>2022</b> ,		
95	Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease.. <b>2022</b> , 5, e222687		0
94	Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?. <b>2022</b> , 1		3
93	Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?. <b>2022</b> , 1		1
92	Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.. <b>2022</b> , 347, 63-67		0
91	Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model. <b>2021</b> ,		2
90	Familial hypercholesterolaemia: a study protocol for identification and investigation of potential causes and markers of subclinical coronary artery disease in the Faroe Islands.. <b>2022</b> , 12, e050857		0
89	Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia.. <b>2022</b> , 13, 872056		0
88	Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication.. <b>2022</b> ,		0
87	An update on lipid apheresis for familial hypercholesterolemia.. <b>2022</b> , 1		1
86	Cardiovascular Risk and Treatment Outcomes in Severe Hypercholesterolemia: A Nationwide Cohort Study.. <b>2022</b> , e024379		2

- 85 Blood lipids and molecular pathways of atherogenesis. **2022**, 623-637
- 84 A Selective Screening Strategy Performed in Pre-School Children and Siblings to Detect Familial Hypercholesterolemia. **2022**, 9, 590 0
- 83 Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. **2022**, 34, 41-51
- 82 [Genetic diseases of lipid metabolism - Focus familial hypercholesterolemia].. **2022**, 147, e50-e61
- 81 Recent Advances on Familial Hypercholesterolemia in Children and Adolescents. **2022**, 10, 1043 3
- 80 Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.. **2022**, 13, 905941 1
- 79 Polygenic Risk Scores. **2022**, 429-446
- 78 Genetic Architecture And Clinical Outcomes Of The Fredrickson-Levy-Lees Dyslipoproteinemias.
- 77 A scoping review of interventions increasing screening and diagnosis of familial hypercholesterolemia. **2022**,
- 76 Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects. 9, 0
- 75 Healthcare worker-based opportunistic screening for familial hypercholesterolemia in a low-resource setting. **2022**, 17, e0269605
- 74 NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. **2022**, 3
- 73 Visual Coronary and Aortic Calcium Scoring on Chest Computed Tomography Predict Mortality in Patients With Low-Density Lipoprotein-Cholesterol  $\geq 90$  mg/dL. **2022**, 15, 0
- 72 Secondary genomic findings in the 2020 China Neonatal Genomes Project participants.
- 71 Coronary Artery and Thoracic Aorta Calcification and Cardiovascular Events in Severe Hypercholesterolemia: More Wood for the Cardiovascular Disease Risk Heterogeneity Bonfire!. **2022**, 15,
- 70 Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications. 10, 0
- 69 2022 Taiwan lipid guidelines for primary prevention. **2022**, 1
- 68 Subclinical Atherosclerosis Determined by Coronary Artery Calcium Deposition in Patients with Clinical Familial Hypercholesterolemia.

67	Clinical Aspects of Genetic and Non-Genetic Cardiovascular Risk Factors in Familial Hypercholesterolemia. <b>2022</b> , 13, 1158	0
66	Addressing the routine failure to clinically identify monogenic cases of common disease. <b>2022</b> , 14,	0
65	Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. <b>2022</b> , 13,	0
64	Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.	1
63	Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction.	1
62	The Inherited Hypercholesterolemias. <b>2022</b> ,	0
61	Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. <b>2022</b> , 49, 47-55	
60	Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect. <b>2022</b> , 23, 8384	1
59	Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. <b>2022</b> ,	0
58	Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia. <b>2022</b> ,	
57	Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients.	1
56	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <b>2022</b> ,	4
55	Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report. 9,	
54	The Malaysian HEalth and WellBeing Assessment (MyHEBAT) Study Protocol: An Initiation of a National Registry for Extended Cardiovascular Risk Evaluation in the Community. <b>2022</b> , 19, 11789	0
53	Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia. <b>2022</b> , 10, 2144	1
52	Ghtique des dyslipidmies, actualit�s et int�r� en m�decine pratique. <b>2022</b> ,	0
51	Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations.	1
50	The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia.	0



49	A pragmatic clinical trial of cascade testing for familial hypercholesterolemia. <b>2022,</b>	0
48	Measured Blood Pressure, Genetically Predicted Blood Pressure, and Cardiovascular Disease Risk in the UK Biobank.	1
47	A mechanism-based operational definition and classification of hypercholesterolemia. <b>2022,</b>	0
46	Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia.	1
45	Impact of variants of uncertain significance of LDL receptor on phenotypes of familial hypercholesterolemia. <b>2022,</b>	0
44	Genetic and molecular architecture of familial hypercholesterolemia.	1
43	Population genomic screening: Ethical considerations to guide age at implementation. 13,	0
42	The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US. <b>2022,</b> 12, 100393	0
41	Electronic health record-based facilitation of familial hypercholesterolaemia detection Sensitivity of different algorithms in genetically confirmed patients.	0
40	Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis. <b>2022,</b> 10, 2639	0
39	Whole genome sequence analysis of blood lipid levels in >66,000 individuals. <b>2022,</b> 13,	1
38	Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease.	0
37	Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome. <b>2022,</b>	0
36	Atherosclerotic Cardiovascular Risk as an Emerging Priority in Pediatrics. <b>2022,</b> 150,	0
35	Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a). <b>2022,</b> 21,	0
34	Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention. <b>2022,</b> 12, 1065	1
33	Genetic testing for Familial Hypercholesterolemia: utility beyond diagnosis.	0
32	New Trends and Therapies for Familial Hypercholesterolemia. <b>2022,</b> 11, 6638	0

- 31 Subclinical atherosclerosis determined by coronary artery calcium deposition in patients with clinical familial hypercholesterolemia. **2022,** ○
- 30 Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?. **2022,** ○
- 29 Stellenwert primärer Fettstoffwechselstörungen im Kontext aktueller Dyslipidämie-Leitlinien und aktueller Innovationen in der Lipidtherapie. ○
- 28 Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics. **2022,** ○
- 27 Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia. **2022,** ○
- 26 The Advantages and Pitfalls of Genetic Analysis in the Diagnosis and Management of Lipid Disorders. **2022,** 101719 ○
- 25 Klinik, Diagnose und Therapie der familiären Hypercholesterinämie. **2022,** 164, 48-53 ○
- 24 CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease. 9, ○
- 23 Genetically transitional disease: a new concept in genomic medicine. **2022,** ○
- 22 Adherence to Statin Treatment in Patients with Familial Hypercholesterolemia: a Dynamic Prediction Model. **2022,** ○
- 21 Cardiovascular disease onset in old people with severe hypercholesterolemia. **2022,** ○
- 20 A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. **2022,** ○
- 19 Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. ○
- 18 Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). **2023,** 16, 44 ○
- 17 Impact of Healthy Lifestyle in Patients With Familial Hypercholesterolemia. **2023,** ○
- 16 Healthy Lifestyles and Cardiovascular Disease in Familial Hypercholesterolemia. **2023,** ○
- 15 Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. **2023,** ○
- 14 Heart Disease and Stroke Statistics 2023 Update: A Report From the American Heart Association. 9

- 13 Clinical Evaluation of Patients with Genetically Confirmed Familial Hypercholesterolemia. **2023**, 12, 1030 ○
- 12 Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. **2023**, 8, 258 1
- 11 Genetic Heterogeneity of Familial Hypercholesterolemia: Repercussions for Molecular Diagnosis. **2023**, 24, 3224 ○
- 10 Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results. **2023**, 16, ○
- 9 Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?. **2023**, 34, 52-58 ○
- 8 Genetic Testing in Familial Hypercholesterolemia: Is It for Everyone?. **2023**, 25, 127-132 ○
- 7 How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. **2023**, 14, 669 ○
- 6 Une histoire familiale d'hypercholestérolémie et le rôle de la génétique. **2023**, 112, 245-249 ○
- 5 Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial. ○
- 4 Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review. **2023**, 13, e065551 ○
- 3 Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia. **2023**, 23, ○
- 2 Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study. **2023**, 373, 10-16 ○
- 1 Familial Hypercholesterolemia: Challenges for a High-Risk Population. **2023**, 81, 1621-1632 ○